Fine tuning therapeutic targeting of the sphingolipid biosynthetic pathway to treat atherosclerosis

Current Vascular Pharmacology

Volumn 4, Issue 2, 2006, Pages 151-154

  Kim, W Scott ^a   Chalfant, Charles E ^b   Garner, Brett ^a  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

ABCA 1; Atherosclerosis; Ceramide kinase; Ceramide 1 phosphate; Glycosphingolipids; Myriocin; Sphingolipid inhibitors; Sphingomyelin

Indexed keywords

GLYCOSPHINGOLIPID; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE;

ATHEROSCLEROSIS; BIOSYNTHESIS; LIPID BLOOD LEVEL; NONHUMAN; REVIEW; ANIMAL; DRUG DELIVERY SYSTEM; HUMAN;

ANIMALS; ATHEROSCLEROSIS; DRUG DELIVERY SYSTEMS; HUMANS; SPHINGOLIPIDS;

EID: 33646024031     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106776359844     Document Type: Review

References (40)

1. Smith EB. Intimal and medial lipids in human aortas. Lancet 1960; 1: 799-803.
2. Breckenridge WC, Halloran JL, Kovacs K, Silver MD. Increase of gangliosides in atherosclerotic human aortas. Lipids 1975; 10: 256-259.
3. Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20: 2614-8.
4. Garner B, Priestman DA, Stocker R, Harvey DJ, Butters TD, Platt FM. Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice. J Lipid Res 2002; 43: 205-14.
5. Levade T, Auge N, Veldman RJ, Cuvillier O, Negre-Salvayre A, Salvayre R. Sphingolipid mediators in cardiovascular cell biology and pathology. Circ Res 2001; 89: 957-68.
6. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol 1998; 18: 1523-33.
7. Johns DG, Charpie JR, Webb RC. Is ceramide signaling a target for vascular therapeutic intervention? Curr Pharm Des 1998; 4: 481-8.
8. Tamama K, Okajima F. Sphingosine 1-phosphate signaling in atherosclerosis and vascular biology. Curr Opin Lipidol 2002; 13: 489-95.
9. Yancey PG, de la Llera-Moya M, Swarnakar S, Monzo P, Klein SM, Connelly MA, et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 2000; 275: 36596-604.
10. Subbaiah PV, Liu M. Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction. J Biol Chem 1993; 268: 20156-63.
11. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996; 98: 1455-64.
12. Leventhal AR, Chen W, Tall AR, Tabas I. Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J Biol Chem 2001; 276: 44976-83.
13. Kinscherf R, Claus R, Wagner M, Gehrke C, Kamencic H, Hou D, et al. Apoptosis caused by oxidized LDL is manganese superoxide dismutase and p53 dependent. Faseb J 1998; 12: 461-7.
14. Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via ceramide. Biochem J 1998; 335: 465-80..
15. Park TS, Panek RL, Mueller SB, Hanselman JC, Rosebury WS, Robertson AW, et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004; 110: 3465-71.
16. Hojjati MR, Li Z, Zhou H, Tang S, Huan C, Ooi E, et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005; 280: 10284-9.
17. Miyake Y, Kozutsumi Y, Nakamura S, Fujita T, Kawasaki T. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun 1995; 211: 396-403.
18. Ballantyne CM, Herd JA, Dunn JK, Jones PH, Farmer JA, Gotto AM Jr. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol 1997; 8: 354-61.
19. Garner B, Mellor HR, Butters TD, Dwek RA, Platt FM. Modulation of THP-1 macrophage and cholesterol-loaded foam cell apolipoprotein-E levels by glycosphingolipids. Biochem Biophys Res Commun 2002; 290: 1361-7.
20. Glaros EN, Kim WS, Quinn CM, Wong J, Gelissen I, Jessup W, et al. Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1 / apoA-I pathway. 1-Phenyl-2-Decanoylamino-3-Morpholino-1-Propanol is a novel cholesterol efflux accelerator. J Biol Chem 2005; 280: 24515-23.
21. Gong N, Wei H, Chowdhury SH, Chatterjee S. Lactosylceramide recruits PKCalpha/epsilon and phospholipase A2 to stimulate PECAM-1 expression in human monocytes and adhesion to endothelial cells. Proc Natl Acad Sci USA 2004; 101: 6490-5.
22. Bhunia AK, Han H, Snowden A, Chatterjee S. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J Biol Chem 1997; 272: 15642-9..
23. Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S, et al. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 2005; 111: 629-32.
24. Pettus BJ, Bielawska A, Subramanian P, Wijesinghe DS, Maceyka M, Leslie CC, et al. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem 2004; 279: 11320-6.
25. Subramanian P, Stahelin RV, Szulc Z, Bielawska A, Cho W, Chalfant CE. Ceramide 1-phosphate acts as a positive allosteric activator of group IVA cytosolic phospholipase A2alpha and enhances the interaction of the enzyme with phosphatidylcholine. J Biol Chem 2005; 280: 17601-7.
26. Pettus BJ, Kitatani K, Chalfant CE, Taha TA, Kawamori T, Bielawski J, et al. The Coordination of Prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1- phosphate. Mol Pharmacol 2005; 68(2): 330-5.
27. Pettus BJ, Chalfant CE, Hannun YA. Sphingolipids in inflammation: roles and implications. Curr Mol Med 2004; 4: 405-18.
28. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P. Phospholipase A(2) in vascular disease. Circ Res 2001; 89: 298-304.
29. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001; 104: 921-7.
30. Pettus BJ, Bielawska A, Spiegel S, Roddy P, Hannun YA, Chalfant CE. Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release. J Biol Chem 2003; 278: 38206-13.
31. Wijesinghe DS, Massiello A, Subramanian P, Szulc Z, Bielawska A, Chalfant CE. Substrate specificity of human ceramide kinase. J Lipid Res 2005; 46: 2706-16.
32. Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 1994; 269: 8362-5.
33. Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, et al. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 2004; 58: 382-93.
34. Triola G, Fabrias G, Dragusin M, Niederhausen L, Broere R, Llebaria A, et al. Specificity of the dihydroceramide desaturase inhibitor N-[(1R, 2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]o ctanamide (GT11) in primary cultured cerebellar neurons. Mol Pharmacol 2004; 66: 1671-8.
35. Inokuchi J, Radin NS. Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase. J Lipid Res 1987; 28: 565-71.
36. Kaminska J, Dzieciol J, Koscielak J. Triazine dyes as inhibitors and affinity ligands of glycosyltransferases. Glycoconj J 1999; 16: 719-23.
37. Takayama S, Chung SJ, Igarashi Y, Ichikawa Y, Sepp A, Lechler RI, et al. Selective inhibition of beta-1, 4- and alpha-1, 3- galactosyltransferases: donor sugar-nucleotide based approach. Bioorg Med Chem 1999; 7: 401-9.
38. Skropeta D, Schworer R, Haag T, Schmidt RR. Asymmetric synthesis and affinity of potent sialyltransferase inhibitors based on transition-state analogues. Glycoconj J 2004; 21: 205-19.
39. Lin TW, Chang WW, Chen CC, Tsai YC. Stachybotrydial, a potent inhibitor of fucosyltransferase and sialyltransferase. Biochem Biophys Res Commun 2005; 331: 953-7.
40. Auge N, Negre-Salvayre A, Salvayre R, Levade T. Sphingomyelin metabolites in vascular cell signaling and atherogenesis. Prog Lipid Res 2000; 39: 207-29.